Saniona AB
10.71
SEK
-0.24
(-2.19%)
ISIN
SE0005794617
Return %
Stock
S&P 500
1Y
-26.24
14.20
3Y
137.92
81.12
5Y
6.90
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Thomas Feldthus
- Full Time Employees
- 34
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Murervangen 42 Glostrup CD Denmark 2600
- IPO Date
- Apr 22, 2014
- Website
- saniona.com
- Similar Companies
- Business
- Saniona AB (publ) (SANION.ST) is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative ion channel modulators for neurological, psychiatric, and rare disorders. The company leverages its proprietary IONBASE database, comprising over 25,000 proprietary molecules targeting ion channels such as GABAA receptors, nicotinic acetylcholine receptors, and potassium channels including Kv7.2/7.3 and KCa3.1, to advance a pipeline addressing epilepsy, major depressive disorder, essential tremor, inflammatory bowel disease, hypothalamic obesity, and Prader-Willi syndrome. Core internal programs include the preclinical GABAA α2/α3/α5 positive allosteric modulator SAN2219 for acute repetitive seizures and other epilepsy indications; the preclinical GABAA α5 negative allosteric modulator SAN2465 for major depressive disorder and potentially Dup15q syndrome; Tesomet, a fixed-dose combination of tesofensine and metoprolol ready for Phase 2b trials in hypothalamic obesity and Prader-Willi syndrome; and SAN903, a KCa3.1 inhibitor ready for Phase 1 trials in inflammatory bowel disease. Partnered programs encompass SAN2355 (Kv7.2/7.3 activator, licensed to Jazz Pharmaceuticals in August 2025 for epilepsy with a USD 42.5 million upfront payment and up to USD 992.5 million in milestones plus royalties); ACP-711/SAN711 (GABAA α3 positive allosteric modulator, licensed to Acadia Pharmaceuticals in November 2024 for essential tremor and neurological diseases with a USD 28 million upfront and up to USD 582 million in milestones plus royalties, Phase 2 planned for 2026); and tesofensine (monoamine reuptake inhibitor for obesity, licensed to Medix with a regulatory submission under review in Mexico); alongside research collaborations with Boehringer Ingelheim (schizophrenia), AstronauTx (Alzheimer's), and Cephagenix (migraine). Within the last year, Saniona secured transformative partnerships with Acadia and Jazz, generating over SEK 700 million in upfront payments to fund internal pipeline advancement; completed a TO4 warrant exercise raising SEK 111 million in April 2025 and convertible conversion from Fenja Capital for SEK 6 million in June 2025; acquired its headquarters in Glostrup, Denmark, for SEK 72 million in June 2025 to ensure operational stability; appointed Johnny Stilou as CFO in May 2025; and progressed preclinical milestones including candidate selection from its mature GABA program for developmental epileptic encephalopathy with spike-wave activation in sleep. Founded in 2011 and headquartered at Smedeland 26B in Glostrup, Denmark, with its parent company registered in Malmö, Sweden, Saniona operates primarily in Europe and the United States, targeting patients with high unmet needs in rare and neurological diseases through global or region-specific licenses. The company maintains 29 employees and trades on Nasdaq Stockholm, with cash reserves of SEK 308 million as of June 30, 2025, supporting Phase 1/2 trials for multiple assets.